KLWA
NVO

Kelly Lawrence W & Associates’s Novo Nordisk NVO Stock Holding History

Kelly Lawrence W & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.5K Hold
450
– – ﹤0.01% 119
2025
Q4 		$22.9K Hold
450
– – 0.01% 119
2025
Q3 		$25K Hold
450
– – 0.01% 131
2025
Q2 		$31.1K Hold
450
– – 0.01% 124
2025
Q1 		$31.2K Hold
450
– – 0.01% 128
2024
Q4 		$38.7K Buy
+450
New +$48.7K 0.01% 121

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Kelly Lawrence W & Associates's NVO Position: Q1 2026 in Review

Kelly Lawrence W & Associates held its Novo Nordisk (NVO) position steady in Q1 2026 at 450 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #119.

Kelly Lawrence W & Associates first reported a position in NVO in Q4 2024 and has held it in 6 quarters since. The position peaked at $38.7K in Q4 2024. 1,270 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Kelly Lawrence W & Associates held 450 shares of Novo Nordisk worth $16.5K as of Q1 2026.
  • Kelly Lawrence W & Associates left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up ﹤0.01% of Kelly Lawrence W & Associates's portfolio in Q1 2026, its #119 holding.
  • Kelly Lawrence W & Associates first reported a position in Novo Nordisk in Q4 2024 and has held it in 6 quarters since.
  • Kelly Lawrence W & Associates's Novo Nordisk position peaked at $38.7K in Q4 2024.
  • 1,270 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Kelly Lawrence W & Associates's 13F filing for Q1 2026, filed 15 May 2026.